Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer (Q36451131)

14 August 2017

1 reference

title

Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer (English)

1 reference

14 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

Lajos Pusztai

1 reference

14 August 2017

Francisco J Esteva

series ordinal

1 reference

14 August 2017

publication date

1 March 2006

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

1 reference

14 August 2017

page(s)

187-191

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Optimal duration of therapy with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Clinical cardiac tolerability of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900500524629

10.1080/07357900500524629

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference